AVA 4746

Drug Profile

AVA 4746

Alternative Names: AVA4746; TBC 4746

Latest Information Update: 02 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Aviara Pharmaceuticals; Encysive Pharmaceuticals; Pfizer; Schering-Plough
  • Class Small molecules
  • Mechanism of Action Integrin alpha4beta1 antagonists; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Stem cell mobilisation
  • Discontinued Asthma; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 17 Jan 2017 Preclinical trials in Stem cell mobilisation in USA (unspecified route)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute lymphoblastic leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 11 Jun 2008 Encysive Pharmaceuticals has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top